Nico Chen is ranked #1814 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Nico Chen (DBS) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Nico Chen's stock ratings?

About 48% of Nico's ratings were profitable over a one-year hold, with an average return of +0.4% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Nico Chen

DBS

Nico Chen

DBS

Wall Street Analyst

★★☆☆☆

#1814

on 13Foresight · ranked by our own returns

48%

Success Rate

+0.3%

Average Return

11 of 23 calls profitable · -131.0% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 5-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 48% of Nico Chen's ratings turned a profit when each position was held for 1 year — averaging +0.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

14 Buy 9 Hold 0 Sell

Nico's Stock Coverage 37 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
HK:2252 Shanghai MicroPort MedBot (Group) Co., Ltd. Class H	Mar 30, 2026	BUY	Strong Buy +40.9% avg upside 1 analyst	$33.00 40.95% Upside	·
SYK Stryker	Mar 18, 2026	BUY	Strong Buy +24.0% avg upside 36 analysts	$450.00 46.12% Upside	-12.7%
MDT Medtronic	Mar 18, 2026	HOLD	Buy +23.5% avg upside 38 analysts	$90.00 13.51% Upside	-8.3%
ISRG Intuitive Surgical	Mar 18, 2026	HOLD	Strong Buy +29.4% avg upside 36 analysts	$480.00 18.04% Upside	-14.8%
ATR AptarGroup	Mar 18, 2026	BUY	Buy +14.4% avg upside 14 analysts	$170.00 41.22% Upside	-4.7%
CH:DAE Daetwyler Holding	Mar 17, 2026	BUY	Strong Buy +19.2% avg upside 4 analysts	$190.00 17.51% Upside	·
ABBV AbbVie	Feb 25, 2026	HOLD	Buy +2.9% avg upside 43 analysts	$230.00 6.33% Upside	-1.7%
JNJ Johnson & Johnson	Feb 24, 2026	HOLD	Strong Buy -3.5% avg upside 36 analysts	$240.00 5.13% Upside	-6.7%
DE:SHL Siemens Healthineers AG	Feb 24, 2026	BUY	Strong Buy +51.7% avg upside 22 analysts	$52.00 51.96% Upside	·
CH:LONN Lonza Group Ltd	Feb 02, 2026	BUY	Strong Buy +26.0% avg upside 19 analysts	$670.00 34.35% Upside	·
WST West Pharmaceutical Services	Jan 28, 2026	BUY	Strong Buy +6.5% avg upside 17 analysts	$320.00 2.36% Downside	+39.8%
GEHC GE Healthcare Technologies Inc	Jan 28, 2026	BUY	Strong Buy +36.0% avg upside 20 analysts	$100.00 62.43% Upside	-22.3%
MRNA Moderna	Jan 28, 2026	HOLD	Hold +6.1% avg upside 38 analysts	$45.00 29.71% Downside	+41.2%
MRK Merck & Company	Jan 28, 2026	BUY	Strong Buy +10.7% avg upside 43 analysts	$130.00 14.10% Upside	+9.6%
AMGN Amgen	Jan 22, 2026	BUY	Buy -11.6% avg upside 57 analysts	$400.00 18.40% Upside	-1.3%
GB:0QIU Novo Nordisk	Jan 22, 2026	HOLD	Hold +43.2% avg upside 28 analysts	$380.00 29.52% Upside	·
REGN Regeneron	Jan 22, 2026	BUY	Strong Buy +26.9% avg upside 57 analysts	$910.00 49.11% Upside	-19.3%
VRTX Vertex Pharmaceuticals	Jan 19, 2026	BUY	Strong Buy -2.6% avg upside 61 analysts	$540.00 19.59% Upside	+3.8%
LLY Eli Lilly & Co	Jan 02, 2026	BUY	Strong Buy -10.5% avg upside 47 analysts	$1333.00 21.25% Upside	+2.0%
HK:2269 Wuxi Biologics (Cayman)	Aug 26, 2025	HOLD	Buy +22.5% avg upside 4 analysts	$36.00 16.87% Upside	·
SNY Sanofi	Jun 03, 2025	BUY	Strong Buy +74.4% avg upside 20 analysts	$66.00 55.65% Upside	-9.1%
PFE Pfizer	May 30, 2025	BUY	Buy +34.2% avg upside 45 analysts	$30.00 18.99% Upside	+19.2%
GILD Gilead Sciences	May 30, 2025	BUY	Strong Buy -4.8% avg upside 66 analysts	$125.00 1.04% Upside	+25.4%
BDX Becton Dickinson	May 21, 2025	HOLD	Buy +35.5% avg upside 25 analysts	—	+10.0%
HCA HCA Healthcare	May 21, 2025	HOLD	Buy +14.7% avg upside 35 analysts	—	+3.3%
BSX Boston Scientific	Mar 31, 2025	BUY	Strong Buy +72.9% avg upside 38 analysts	$130.00 187.13% Upside	-37.8%
SHTDY Sinopharm Group Co	Mar 03, 2025	HOLD	Strong Buy 2 analysts	—	+10.8%
HK:0853 MicroPort Scientific	Mar 03, 2025	HOLD	Hold 1 analyst	—	·
JP:4543 Terumo	Oct 15, 2024	BUY	Strong Buy +68.2% avg upside 4 analysts	$3200.00 43.88% Upside	·
HK:1066 Shandong Weigao Group Medical Polymer Co	Sep 02, 2024	BUY	Strong Buy +97.0% avg upside 1 analyst	$6.40 97.01% Upside	·
HK:1681 Consun Pharmaceutical Group Ltd.	Aug 22, 2024	BUY	Strong Buy 1 analyst	—	·
HK:1801 Innovent Biologics	Aug 01, 2024	HOLD	Strong Buy +32.6% avg upside 7 analysts	—	·
HK:1099 Sinopharm Group Co	Mar 26, 2024	BUY	Strong Buy +78.9% avg upside 1 analyst	$29.30 78.91% Upside	·
AMPH Amphastar Pharmaceuticals	Nov 24, 2023	BUY	Hold +42.4% avg upside 11 analysts	$55.00 192.48% Upside	-20.1%
STVN Stevanato Group	Nov 03, 2023	HOLD	Strong Buy +53.7% avg upside 13 analysts	$30.00 71.01% Upside	·
DE:GXI Gerresheimer	Oct 10, 2023	BUY	Buy +143.3% avg upside 14 analysts	$120.00 368.84% Upside	·
CRL Charles River Labs	Aug 22, 2023	HOLD	Strong Buy +11.9% avg upside 34 analysts	$188.70 1.96% Upside	+0.5%

🔒 32 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Nico Chen — Frequently Asked Questions

How accurate are Nico Chen's stock ratings?

Based on the calls 13Foresight could measure, about 48% of Nico's ratings were profitable over a one-year hold, with an average return of +0.4% per rating, or -16.0% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Nico ranked on 13Foresight?

Nico Chen is currently ranked #1814 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Nico cover?

Nico most recently has ratings on HK:2252, SYK, MDT, ISRG, ATR, CH:DAE, ABBV, JNJ, DE:SHL, CH:LONN, WST, GEHC and 25 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!